Current and Emerging Medical Therapies for Dizziness
Copyright © 2021 Elsevier Inc. All rights reserved..
Medical therapies for dizziness are aimed at vertigo reduction, secondary symptom management, or the root cause of the pathologic process. Acute peripheral vertigo pharmacotherapies include antihistamines, calcium channel blockers, and benzodiazepines. Prophylactic pharmacotherapies vary between causes. For Meniere disease, betahistine and diuretics remain initial first-line oral options, whereas intratympanic steroids and intratympanic gentamicin are reserved for uncontrolled symptoms. For cerebellar dizziness and oculomotor disorders, 4-aminopyridine may provide benefit. For vestibular migraine, persistent postural perceptual dizziness and mal de débarquement, treatment options overlap and include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants and calcium channel blockers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Otolaryngologic clinics of North America - 54(2021), 5 vom: 02. Okt., Seite 1037-1056 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Raymond, Mallory J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Central vertigo |
|---|
| Anmerkungen: |
Date Completed 25.11.2021 Date Revised 25.11.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.otc.2021.05.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330802739 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330802739 | ||
| 003 | DE-627 | ||
| 005 | 20231225212054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.otc.2021.05.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330802739 | ||
| 035 | |a (NLM)34538357 | ||
| 035 | |a (PII)S0030-6665(21)00120-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Raymond, Mallory J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current and Emerging Medical Therapies for Dizziness |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.11.2021 | ||
| 500 | |a Date Revised 25.11.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a Medical therapies for dizziness are aimed at vertigo reduction, secondary symptom management, or the root cause of the pathologic process. Acute peripheral vertigo pharmacotherapies include antihistamines, calcium channel blockers, and benzodiazepines. Prophylactic pharmacotherapies vary between causes. For Meniere disease, betahistine and diuretics remain initial first-line oral options, whereas intratympanic steroids and intratympanic gentamicin are reserved for uncontrolled symptoms. For cerebellar dizziness and oculomotor disorders, 4-aminopyridine may provide benefit. For vestibular migraine, persistent postural perceptual dizziness and mal de débarquement, treatment options overlap and include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants and calcium channel blockers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Central vertigo | |
| 650 | 4 | |a Dizziness | |
| 650 | 4 | |a Peripheral vertigo | |
| 650 | 4 | |a Pharmacotherapy | |
| 650 | 7 | |a Histamine Antagonists |2 NLM | |
| 700 | 1 | |a Vivas, Esther X |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Otolaryngologic clinics of North America |d 1970 |g 54(2021), 5 vom: 02. Okt., Seite 1037-1056 |w (DE-627)NLM000170666 |x 0030-6665 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2021 |g number:5 |g day:02 |g month:10 |g pages:1037-1056 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.otc.2021.05.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2021 |e 5 |b 02 |c 10 |h 1037-1056 | ||